S3-guideline for the treatment of psoriasis vulgaris;S3-leitlinie zur therapie der psoriasis vulgaris

JDDG - Journal of the German Society of Dermatology

Volumn 4, Issue SUPPL. 2, 2006, Pages

  Nast, Alexander ^a   Kopp, Ina B ^b   Augustin, Matthias ^c   Banditt, Kirstin Benita ^a   Boehncke, Wolf Henning ^d   Follmann, Markus ^a,n   Friedrich, Markus ^a,o   Huber, Matthias ^a   Kahl, Christina ^a   Klaus, Joachim ^e   Koza, Joachim ^e   Kreiselmaier, Inga ^f   Mohr, Johannes ^g   Mrowietz, Ulrich ^f   Ockenfels, Hans Michael ^h   Orzechowski, Hans Dieter ^a   Prinz, Jörg ⁱ   Reich, Kristian ^g,p   Rosenbach, Thomas ^j   Rosumeck, Stefanie ^a   Schlaeger, Martin ^k   Schmid Ott, Gerhard ^l   Sebastian, Michael ^e   Streit, Volker ^m   Weberschock, Tobias ^d   Rzany, Berthold ^a   more..

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^d GOETHE UNIVERSITY   (Germany)

^e Deutscher Psoriasis Bund eV ^*  (Germany)

^f UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^g UNIVERSITY OF GÖTTINGEN   (Germany)

^h Haut U Allergieklinik   (Germany)

ⁱ UNIVERSITY OF MUNICH   (Germany)

^j Niedergelassener Dermatologe   (Germany)

^k Niedergelassener Dermatologe   (Germany)

^l HANNOVER MEDICAL SCHOOL   (Germany)

^m Niedergelassener Dermatologe   (Germany)

ⁿ INSTITUTE FOR QUALITY AND EFFICIENCY IN HEALTH CARE IQWIG   (Germany)

^o Intendis GmbH   (Germany)

^p Prof Steinkraus und Partner   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALEFACEPT; BERGAPTEN; BETAMETHASONE DIPROPIONATE; BETAMETHASONE DIPROPIONATE PLUS CALCIPOTRIOL; CALCINEURIN INHIBITOR; CALCIPOTRIOL; CALCITRIOL; CHLORPROMAZINE; CICLORAL; CLOBETASOL PROPIONATE; COLECALCIFEROL DERIVATIVE; CORTICOSTEROID; CYCLOSPORIN; CYCLOSPORIN A; DITHRANOL; DOUGLAN; EFALIZUMAB; ETANERCEPT; ETRETIN; ETRETINATE; FOLINIC ACID; FUMADERM; FUMARIC ACID; GLUCOCORTICOID; HYDROCHLOROTHIAZIDE; INFLIXIMAB; ISOTRETINOIN; LANTAREL; METEX; METHOTREXATE; METHOXSALEN; MOMETASONE FUROATE; OPTORAL; PIMECROLIMUS; PROMETHAZINE; PSORADEXAN; PSORALON; PSORCUTAN BETA; QUINIDINE; RETINOID; STEROID; TACALCITOL; TAZAROTENE; TIAPROFENIC ACID; TSUKUBAENOLIDE; UNINDEXED DRUG;

ACRODERMATITIS; CLINICAL FEATURE; DIAGNOSTIC APPROACH ROUTE; DISEASE CLASSIFICATION; DOSE RESPONSE; DRUG COST; DRUG EFFECT; DRUG MECHANISM; EPITHELIUM TUMOR; EXCIMER LASER; FOLLICULITIS; GENETICS; HEALTH CARE COST; HUMAN; HYPOPIGMENTATION; INCIDENCE; INFECTION; KIDNEY FAILURE; LIVER FAILURE; PATHOGENESIS; PHOTOALLERGY; PHOTOTHERAPY; PSORIASIS VULGARIS; PUSTULOSIS PALMOPLANTARIS; PUVA; REVIEW; SKIN IRRITATION; SKIN NECROSIS; TERATOGENICITY; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; ULTRAVIOLET B RADIATION;

DERMATOLOGIC AGENTS; GERMANY; HUMANS; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES; PSORIASIS;

EID: 33751545239     PISSN: 16100379     EISSN: 16100387     Source Type: Journal    
DOI: 10.1111/j.1610-0387.2006.06142.x     Document Type: Review

References (302)

1. Nevitt GJ und Hutchinson PE. Psoriasis in the community: prevalence, severity and patients' beliefs and attitudes towards the disease. Br J Dermatol 1996; 135(4): 533-7.
2. Schmid-Ott G, Malewski P, Kreiselmaier I, Mrowietz U. Psychosoziale Folgen der Psoriasis - eine empirische Studie über die Krankheitslast bei 3753 Betroffenen. Hautarzt 2005; 56(5): 466-72.
3. Rapp SR, Feldman SR, Exum ML, Fleischer AB, Jr., Reboussin DM. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999; 41(3 Pt 1): 401-7.
4. Stern RS, Nijsten T, Feldman SR, Margolis DJ, Rolstad T. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc 2004; 9(2): 136-9.
5. Richards HL, Fortune DG, O'Sullivan TM, Main CJ, Griffiths CE. Patients with psoriasis and their compliance with medication. J Am Acad Dermatol 1999; 41(4): 581-3.
6. Berger K, Ehlken B, Kugland B, Augustin M. Cost-of-illness in patients with moderate and severe chronic psoriasis vulgaris in Germany. J Dtsch Dermatol Ges 2005; 3(7): 511-8.
7. Traupe H und Robra BP. Robert-Koch-Institut (Hrsg.) Heft 11 (2002), S. 1-15. Berlin. Gesundheitsberichterstattung des Bundes.
8. Van Zuiden Communications (Hrsg.). Richtlijn foto(chemo)therapie en systemische therapie bij ernstige chronische plaque psoriasis. 2003
9. Mason J, Mason AR, Cork MJ. Topical preparations for the treatment of psoriasis: a systematic review. Br J Dermatol 2002; 146(3): 351-64.
10. Augustin M. Pharmako-Ökonomische Angaben. Stand Januar 2006
11. Augustin M, Wulf A, Schloebe A, Zschocke I. Expertise zu Wirksamkeit und Nutzen von Harnstoff in der Therapie chronischer Hautkrankheiten. Wissenschaftliches Gutachten im Auftrag der Deutschen Dermatologischen Gesellschaft. Hamburg, 2004
12. Lebwohl M. The role of salicylic acid in the treatment of psoriasis. Int J Dermatol 1999; 38(1): 16-24.
13. Anonymous. Salicylsäure zur topischen Anwendung. Bundesanzeiger 19.06.1990 Korrektur 20.09.1990 (korrigierte Fassung in ZrvA Dez 1990)
14. Braun-Falco O, Plewig G, Wolff HH. Dermatologie und Venerologie. 5. Aufl. Berlin: Springer, Mai 2005
15. Camisa C. Handbook of Psoriasis. 2. Ed. Oxford: Blackwell, 2004
16. Christophers E, Mrowietz U, Sterry W. Psoriasis - auf einen Blick. 1. Aufl. Berlin: Blackwell, 2002
17. Fritsch P. Dermatologie und Venerologie. 2. Aufl. Berlin: Springer, 2004
18. Katsambas AD und Lotti TM. European Handbook of Dermatological Treatments. 2. Aufl. Berlin: Springer, 2003
19. Korting HC und Sterry W. Therapeutische Verfahren in der Dermatologie. 1. Aufl. Berlin: Blackwell, 2001
20. Lebwohl M, Heymann W, Berth-Jones J, Coulson I. Treatment of Skin Disease. 1. Ed. London: Mosby, 2002
21. Müller-Oerlinghausen. Arzneimittelverordnungen. Im Auftrag der Arzneimittelkommission der Deutschen Ärzteschaft; Dt. Ärzteverlag. Köln: 2003
22. Niedner R und Ziegenmeyer J. Dermatika. 1. Aufl. Stuttgart: Wiss.Verl.-Ges, 1992
23. Orfanos CE und Garbe C. Therapie der Hautkrankheiten. 2. Aufl. Berlin: Springer, 2002
24. Traupe H und Hamm H. Pädiatrische Dermatologie. 1. Aufl. Berlin: Springer, 1999
25. Van de Kerkhof P. Textbook of Psoriasis. 2. Ed. Oxford: Blackwell, 2003
26. Going SM, Guyer BM, Jarvie DR, Hunter JA. Salicylic acid gel for scalp psoriasis. Clin Exp Dermatol 1986; 11(3): 260-2.
27. Hagemann I und Proksch E. Topical treatment by urea reduces epidermal hyperproliferation and induces differentiation in psoriasis. Acta Derm Venereol 1996; 76(5): 353-6.
28. Ross SD und Schachter RK. A randomized comparison of three conventional modes of treatment of psoriasis of the scalp. Cutis 1981; 28(4): 438-9.
29. Swanbeck G. A new treatment of ichthyosis and other hyperkeratotic conditions. Acta Derm Venereol 1968; 48(2): 123-7.
30. Mrowietz U, Graeber M, Brautigam M, Thurston M, Wagenaar A, Weidinger G, Christophers E. The novel ascomycin derivative SDZ ASM 981 is effective for psoriasis when used topically under occlusion. Br J Dermatol 1998; 139(6): 992-6.
31. Remitz A, Reitamo S, Erkko P, Granlund H, Lauerma AI. Tacrolimus ointment improves psoriasis in a microplaque assay. Br J Dermatol 1999; 141(1): 103-7.
32. Zonneveld IM, Rubins A, Jablonska S, Dobozy A, Ruzicka T, Kind P, Dubertret L, Bos JD. Topical tacrolimus is not effective in chronic plaque psoriasis. A pilot study. Arch Dermatol 1998; 134(9): 1101-2.
33. Freeman AK, Linowski GJ, Brady C, Lind L, Vanveldhuisen P, Singer G, Lebwohl M. Tacrolimus ointment for the treatment of psoriasis on the face and intertriginous areas. J Am Acad Dermatol 2003; 48(4): 564-8.
34. Gribetz C, Ling M, Lebwohl M, Pariser D, Draelos Z, Gottlieb AB, Zaias N, Chen DM, Parneix-Spake A, Hultsch T, Menter A. Pimecrolimus cream 1 % in the treatment of intertriginous psoriasis: a double-blind, randomized study. J Am Acad Dermatol 2004; 51(5): 731-8.
35. Amichai B. Psoriasis of the glans penis in a child successfully treated with Elidel (pimecrolimus) cream. J Eur Acad Dermatol Venereol 2004; 18(6): 742-3.
36. Anonymous. Systemic tacrolimus (FK 506) is effective for the treatment of psoriasis in a double-blind, placebo-controlled study. The European FK 506 Multicentre Psoriasis Study Group. Arch Dermatol 1996; 132(4): 419-23.
37. Grassberger M, Baumruker T, Enz A, Hiestand P, Hultsch T, Kalthoff F, Schuler W, Schulz M, Werner FJ, Winiski A, Wolff B, Zenke G. A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: in vitro pharmacology. Br J Dermatol 1999; 141(2): 264-73.
38. O'Keefe SJ, Tamura J, Kincaid RL, Tocci MJ, O'Neill EA. FK-506- and CsA-sensitive activation of the interleukin-2 promoter by calcineurin. Nature 1992; 357(6380): 692-4.
39. Liu J, Farmer JD, Jr., Lane WS, Friedman J, Weissman I, Schreiber SL. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell 1991; 66(4): 807-15.
40. Sperr WR, Agis H, Czerwenka K, Virgolini I, Bankl HC, Muller MR, Zsebo K, Lechner K, Valent P. Effects of cyclosporin A and FK-506 on stem cell factor-induced histamine secretion and growth of human mast cells. J Allergy Clin Immunol 1996; 98(2): 389-99.
41. Schuller E, Oppel T, Bornhovd E, Wetzel S, Wollenberg A. Tacrolimus ointment causes inflammatory dendritic epidermal cell depletion but no Langerhans cell apoptosis in patients with atopic dermatitis. J Allergy Clin Immunol 2004; 114(1): 137-43.
42. Kalthoff FS, Chung J, Musser P, Stuetz A. Pimecrolimus does not affect the differentiation, maturation and function of human monocyte-derived dendritic cells, in contrast to corticosteroids. Clin Exp Immunol 2003; 133(3): 350-9.
43. Carroll CL, Clarke J, Camacho F, Balkrishnan R, Feldman SR. Topical tacrolimus ointment combined with 6 % salicylic acid gel for plaque psoriasis treatment. Arch Dermatol 2005; 141(1): 43-6.
44. Mrowietz U, Wustlich S, Hoexter G, Graeber M, Brautigam M, Luger T. An experimental ointment formulation of pimecrolimus is effective in psoriasis without occlusion. Acta Derm Venereol 2003; 83(5): 351-3.
45. Schroder JM, Kosfeld U, Christophers E. Multifunctional inhibition by anthralin in nonstimulated and chemotactic factor stimulated human neutrophils. J Invest Dermatol 1985; 85(1): 30-4.
46. Mrowietz U, Falsafi M, Schroder JM, Christophers E. Inhibition of human monocyte functions by anthralin. Br J Dermatol 1992; 127(4): 382-6.
47. Anderson R, Lukey PT, Dippenaar U, Eftychis HA, Findlay GH, Wooten MW, Nel AE. Dithranol mediates pro-oxidative inhibition of polymorphonuclear leukocyte migration and lymphocyte proliferation. Br J Dermatol 1987; 117(4): 405-18.
48. Fisher LB und Maibach HI. The effect of anthralin and its derivatives on epidermal cell kinetics. J Invest Dermatol 1975; 64(5): 338-41.
49. Gottlieb AB, Khandke L, Krane JF, Staiano-Coico L, Ashinoff R, Krueger JG. Anthralin decreases keratinocyte TGF-alpha expression and EGF-receptor binding in vitro. J Invest Dermatol 1992; 98(5): 680-5.
50. Kemeny L, Michel G, Arenberger P, Ruzicka T. Down-regulation of epidermal growth factor receptors by dithranol. Acta Derm Venereol 1993; 73(1): 37-40.
51. Ockenfels HM, Nussbaum G, Schultewolter T, Burger PM, Goos M. Cyclosporin A, FK506 and dithranol after tyrosine-specific protein phosphorylation in HaCaT keratinocytes. Arch Dermatol Res 1995; 287(3-4): 304-9.
52. Lebwohl M. Anthralin. Dermatol Ther 1999; 11: 8-13.
53. Silverman A, Menter A, Hairston JL. Tars and anthralins. Dermatol Clin 1995; 13(4): 817-33.
54. Goodfield MJ, Hull SM, Cunliffe WJ. The systemic effect of dithranol treatment in psoriasis. Acta Derm Venereol 1994; 74(4): 295-7.
55. Agarwal R, Saraswat A, Kaur I, Katare OP, Kumar B. A novel liposomal formulation of dithranol for psoriasis: preliminary results. J Dermatol 2002; 29(8): 529-32.
56. Monastirli A, Georgiou S, Pasmatzi E, Sakkis T, Badavanis G, Drainas D, Sagriotis A, Tsambaos D. Calcipotriol plus short-contact dithranol: a novel topical combination therapy for chronic plaque psoriasis. Skin Pharmacol Appl Skin Physiol 2002; 15(4): 246-51.
57. Gerritsen MJ, Boezeman JB, Elbers ME, van de Kerkhof PC. Dithranol embedded in crystalline monoglycerides combined with phototherapy (UVB): a new approach in the treatment of psoriasis. Skin Pharmacol Appl Skin Physiol 1998; 11(3): 133-9.
58. Prins M, Swinkels OQ, Van de Kerkhof PC, Van der Valk PG. The impact of the frequency of short contact dithranol treatment. Eur J Dermatol 2001; 11(3): 214-8.
59. Thune P und Brolund L. Short- and long-contact therapy using a new dithranol formulation in individually adjusted dosages in the management of psoriasis. Acta Derm Venereol Suppl (Stockh) 1992; 172: 28-9.
60. De Mare S, Calis N, den Hartog G, van Erp PE, van de Kerkhof PC. The relevance of salicylic acid in the treatment of plaque psoriasis with dithranol creams. Skin Pharmacol 1988; 1(4): 259-64.
61. Prins M, Swinkels OQ, Bouwhuis S, de Gast MJ, Bouwman-Boer Y, van der Valk PG, van de Kerkhof PC. Dithranol in a cream preparation: disperse or dissolve? Skin Pharmacol Appl Skin Physiol 2000; 13(5): 273-9.
62. Hutchinson PE, Marks R, White J. The efficacy, safety and tolerance of calcitriol 3 microg/g ointment in the treatment of plaque psoriasis: a comparison with short-contact dithranol. Dermatology 2000; 201(2): 139-45.
63. Mahrle G und Schulze HJ. [The effect of initial external glucocorticoid administration on cignolin treatment of psoriasis]. Z Hautkr 1990; 65(3): 282, 285-7.
64. Swinkels OQ, Prins M, Kucharekova M, de Boo T, Gerritsen MJ, van der Valk PG, van de Kerkhof PC. Combining lesional short-contact dithranol therapy of psoriasis with a potent topical corticosteroid. Br J Dermatol 2002; 146(4): 621-6.
65. Van de Kerkhof PC, Green C, Hamberg KJ, Hutchinson PE, Jensen JK, Kidson P, Kragballe K, Larsen FG, Munro CS, Tillman DM. Safety and efficacy of combined high-dose treatment with calcipotriol ointment and solution in patients with psoriasis. Dermatology 2002; 204(3): 214-21.
66. Agrup G und Agdell J. A comparison between Antraderm stick (0.5 % and 1 %) and dithranol paste (0.125 % and 0.25 %) in the treatment of psoriasis. Br J Clin Pract 1985; 39(5): 185-7.
67. Mork NJ, Austad J, Brolund L. An open, parallel groups, study of the importance of thoroughness of application in the treatment of psoriasis with a dithranol cream (Micanol). Acta Derm Venereol Suppl (Stockh) 1992; 172: 23-4.
68. Berth-Jones J, Chu AC, Dodd WA, Ganpule M, Griffiths WA, Haydey RP, Klaber MR, Murray SJ, Rogers S, Jurgensen HJ. A multicentre, parallel-group comparison of calcipotriol ointment and short-contact dithranol therapy in chronic plaque psoriasis. Br J Dermatol 1992; 127(3): 266-71.
69. Mustakallio KK. Irritation and staining by dithranol (anthralin) and related compounds: I. Estimation with chamber testing and contact thermography. Acta Derm Venereol Suppl (Stockh) 1979; 59(85): 125-32.
70. Haustein UF und Lohrisch I. Irritant potential of dithranol. Dermatologica 1986; 173(6): 288-93.
71. Schiavi ME, Belletti B, Seidenari S. Ultrasound description and quantification of irritant reactions induced by dithranol at different concentrations. A comparison with visual assessment and colorimetric measurements. Contact Dermatitis 1996; 34(4): 272-7.
72. Burden AD, Muston H, Beck MH. Intolerance and contact allergy to tar and dithranol in psoriasis. Contact Dermatitis 1994; 31(3): 185-6.
73. Rotstein H und Baker C. The treatment of psoriasis. Med J Aust 1990; 152(3): 153-64.
74. Gottlieb AB, Ford R, Spellman MC. The Efficacy and Tolerability of Clobetasol Propionate Foam 0.05 % in the Treatment of Mild to Moderate Plaque-type Psoriasis of Nonscalp Regions. J Cutan Med Surg 2003; 7(3): 185-92.
75. Chuang TY und Samson CR. Clinical efficacy and safety of augmented betamethasone dipropionate ointment and diflorasone ointment for psoriasis - A multicentre, randomized, double-blinded study. J Dermatol Treat 1991; 2(2): 63-66.
76. Katz HI, Tanner DJ, Cuffie CA, Brody NI, Garcia CJ, Lowe NJ, Medansky RS, Roth HL, Shavin JS, Swinyer LJ. A comparison of the efficacy and saftey of the combination mometasone furoate 0,1 %/salicylic acid 5 % ointment with each of its components in psoriasis. J Derm Treat 1998; 9(3): 151-6.
77. Koo J, Cuffie CA, Tanner DJ, Bressinck R, Cornell RC, DeVillez RL, Edwards L, Breneman DL, Piacquadio DJ, Guzzo CA, Monroe EW. Mometasone furoate 0.1 %-salicylic acid 5 % ointment versus mometasone furoate 0.1 % ointment in the treatment of moderate-to-severe psoriasis: a multicenter study. Clin Ther 1998; 20(2): 283-91.
78. Camarasa JM, Ortonne JP, Dubertret L. Calcitriol shows greater persistence of treatment effect than betamethasone dipropionate in topical psoriasis therapy. J Dermatolog Treat 2003; 14(1): 8-13.
79. Papp KA, Guenther L, Boyden B, Larsen FG, Harvima RJ, Guilhou JJ, Kaufmann R, Rogers S, van de Kerkhof PC, Hanssen LI, Tegner E, Burg G, Talbot D, Chu A. Early onset of action and efficacy of a combination of calcipotriene and betamethasone dipropionate in the treatment of psoriasis. J Am Acad Dermatol 2003; 48(1): 48-54.
80. Douglas WS, Poulin Y, Decroix J, Ortonne JP, Mrowietz U, Gulliver W, Krogstad AL, Larsen FG, Iglesias L, Buckley C, Bibby AJ. A new calcipotriol/betamethasone formulation with rapid onset of action was superior to monotherapy with betamethasone dipropionate or calcipotriol in psoriasis vulgaris. Acta Derm Venereol 2002; 82(2): 131-5.
81. Kaufmann R, Bibby AJ, Bissonnette R, Cambazard F, Chu AC, Decroix J, Douglas WS, Lowson D, Mascaro JM, Murphy GM, Stymne B. A new calcipotriol/betamethasone dipropionate formulation (Daivobet) is an effective once-daily treatment for psoriasis vulgaris. Dermatology 2002; 205(4): 389-93.
82. Stein LF, Sherr A, Solodkina G, Gottlieb AB, Chaudhari U. Betamethasone valerate foam for treatment of nonscalp psoriasis. J Cutan Med Surg 2001; 5(4): 303-7.
83. Decroix J, Pres H, Tsankov N, Poncet M, Arsonnaud S. Clobetasol propionate lotion in the treatment of moderate to severe plaque-type psoriasis. Cutis 2004; 74(3): 201-6.
84. Lebwohl M, Sherer D, Washenik K, Krueger GG, Menter A, Koo J, Feldman SR. A randomized, doubleblind, placebo-controlled study of clobetasol propionate 0.05 % foam in the treatment of nonscalp psoriasis. Int J Dermatol 2002; 41(5): 269-74.
85. Peharda V, Gruber F, Prpic L, Kastelan M, Brajac I. Comparison of mometasone furoate 0.1 % ointment and betamethasone dipropionate 0.05 % ointment in the treatment of psoriasis vulgaris. Acta Derm Venereol Croatica 2000; 8(4): 223-226.
86. Shupack JL, Jondreau L, Kenny C, Stiller MJ. Diflorasone diacetate ointment 0.05 % versus betamethasone dipropionate ointment 0.05 % in moderate-severe plaque-type psoriasis. Dermatology 1993; 186(2): 129-32.
87. Svensson AR, I; Gisslen, H; Nordin; P, Gios, I. A comperative study of mometasone furoate oinment and betamethasone valerate ointment in patients with Psoriasis vulgaris. Curr Ther Res Clin Exp 1992; 52(3): 390-396.
88. Weston WL, Fennessey PV, Morelli J, Schwab H, Mooney J, Samson C, Huff L, Harrison LM, Gotlin R. Comparison of hypothalamus-pituitary-adrenal axis suppression from superpotent topical steroids by standard endocrine function testing and gas chromatographic mass spectrometry. J Invest Dermatol 1988; 90(4): 532-5.
89. Medansky RS, Cuffie CA, Tanner DJ. Mometasone furoate 0.1 %-salicylic acid 5 % ointment twice daily versus fluocinonide 0.05 % ointment twice daily in the management of patients with psoriasis. Clin Ther 1997; 19(4): 701-9.
90. Housman TS, Keil KA, Mellen BG, McCarty MA, Fleischer AB, Jr., Feldman SR. The use of 0.25 % zinc pyrithione spray does not enhance the efficacy of clobetasol propionate 0.05 % foam in the treatment of psoriasis. J Am Acad Dermatol 2003; 49(1): 79-82.
91. Bagatell F. Management of psoriasis: A clinical evaluation of the dermatological patch, Actidermregistered trade mark, over a topical steroid. Adv Ther 1988; 5(6): 291-296.
92. Fabry H und Yawalkar SJ. A comparative multicentre trial of halometasone ointment and fluocortolone plus fluocortolone caproate ointment in the treatment of psoriasis. J Int Med Res 1983; 11(Suppl 1): 26-30.
93. Miller JJ, Roling D, Margolis D, Guzzo C. Failure to demonstrate therapeutic tachyphylaxis to topically applied steroids in patients with psoriasis. J Am Acad Dermatol 1999; 41(4): 546-9.
94. Grupper C. The chemistry, pharmacology and use of tar in treatment of psoriasis. In: Farber EM, Cox AJ, eds. Psoriasis: Proceeding of International Symposium. Stanford: Stanford University, 1971: 347-56.
95. Belsito DV und Kechijian P. The role of tar in Goeckerman therapy. Arch Dermatol 1982; 118(5): 319-21.
96. Diette KM, Momtaz K, Stern RS, Arndt KA, Parrish JA. Role of ultraviolet A in phototherapy for psoriasis. J Am Acad Dermatol 1984; 11(3): 441-7.
97. LeVine MJ und Parrish JA. The effect of topical fluocinonide ointment on phototherapy of psoriasis. J Invest Dermatol 1982; 78(2): 157-9.
98. Frost P, Horwitz SN, Caputo RV, Berger SM. Tar gel-phototherapy for psoriasis. Combined therapy with suberythemogenic doses of fluorescent sunlamp ultraviolet radiation. Arch Dermatol 1979; 115(7): 840-6.
99. Hauptverband der gewerblichen Berufsgenossenschaften e.V. Berufsgenossenschaftliche Grundsätze für arbeitsmedizinische Vorsorgeuntersuchungen bei Einwirkung krebserzeugender Arbeitsstoffe. Arbeitsmed, Sozialmed, Präventivmed 1982(17): 228-38
100. Lee WR, Alderson MR, Downes JE. Scrotal cancer in the north-west of England, 1962-68. Br J Ind Med 1972; 29(2): 188-95.
101. Diette KM, Momtaz TK, Stern RS, Arndt KA, Parrish JA. Psoralens and UV-A and UV-B twice weekly for the treatment of psoriasis. Arch Dermatol 1984; 120(9): 1169-73.
102. Weinstein GD, Koo JY, Krueger GG, Lebwohl MG, Lowe NJ, Menter MA, Lew-Kaya DA, Sefton J, Gibson JR, Walker PS. Tazarotene cream in the treatment of psoriasis: Two multicenter, double-blind, randomized, vehicle-controlled studies of the safety and efficacy of tazarotene creams 0.05 % and 0.1 % applied once daily for 12 weeks. J Am Acad Dermatol 2003; 48(5): 760-7.
103. Gollnick H und Menter A. Combination therapy with tazarotene plus a topical corticosteroid for the treatment of plaque psoriasis. Br J Dermatol 1999; 140(Suppl 54): 18-23.
104. Green L und Sadoff W. A clinical evaluation of tazarotene 0.1 % gel, with and without a high- or mid-high-potency corticosteroid, in patients with stable plaque psoriasis. J Cutan Med Surg 2002; 6(2): 95-102.
105. Koo JY und Martin D. Investigator-masked comparison of tazarotene gel q.d. plus mometasone furoate cream q.d. vs. mometasone furoate cream b.i.d. in the treatment of plaque psoriasis. Int J Dermatol 2001; 40(3): 210-2.
106. Lebwohl M. Strategies to optimize efficacy, duration of remission, and safety in the treatment of plaque psoriasis by using tazarotene in combination with a corticosteroid. J Am Acad Dermatol 2000; 43(2 Pt 3): S43-6.
107. Poulin YP. Tazarotene 0.1 % gel in combination with mometasone furoate cream in plaque psoriasis: a photographic tracking study. Cutis 1999; 63(1): 41-8.
108. Boonstra A, Barrat FJ, Crain C, Heath VL, Savelkoul HF, O'Garra A. 1alpha,25-Dihydroxyvitamin d3 has a direct effect on naive CD4(+) T cells to enhance the development of Th2 cells. J Immunol 2001; 167(9): 4974-80.
109. Takeuchi A, Reddy GS, Kobayashi T, Okano T, Park J, Sharma S. Nuclear factor of activated T cells (NFAT) as a molecular target for 1alpha,25-dihydroxyvitamin D3-mediated effects. J Immunol 1998; 160(1): 209-18.
110. Guenther L, Van de Kerkhof PC, Snellman E, Kragballe K, Chu AC, Tegner E, Garcia-Diez A, Springborg J. Efficacy and safety of a new combination of calcipotriol and betamethasone dipropionate (once or twice daily) compared to calcipotriol (twice daily) in the treatment of psoriasis vulgaris: a randomized, double-blind, vehicle-controlled clinical trial. Br J Dermatol 2002; 147(2): 316-23.
111. Kragballe K, Noerrelund KL, Lui H, Ortonne JP, Wozel G, Uurasmaa T, Fleming C, Estebaranz JL, Hanssen LI, Persson LM. Efficacy of once-daily treatment regimens with calcipotriol/betamethasone dipropionate ointment and calcipotriol ointment in psoriasis vulgaris. Br J Dermatol 2004; 150(6): 1167-73.
112. Ortonne JP, Kaufmann R, Lecha M, Goodfield M. Efficacy of treatment with calcipotriol/betamethasone dipropionate followed by calcipotriol alone compared with tacalcitol for the treatment of psoriasis vulgaris: a randomised, double-blind trial. Dermatology 2004; 209(4): 308-13.
113. Guenther LC, Poulin YP, Pariser DM. A comparison of tazarotene 0.1 % gel once daily plus mometasone furoate 0.1 % cream once daily versus calcipotriene 0.005 % ointment twice daily in the treatment of plaque psoriasis. Clin Ther 2000; 22(10): 1225-38.
114. Lebwohl M, Yoles A, Lombardi K, Lou W. Calcipotriene ointment and halobetasol ointment in the long-term treatment of psoriasis: effects on the duration of improvement. J Am Acad Dermatol 1998; 39(3): 447-50.
115. Austad J, Bjerke JR, Gjertsen BT, Helland S, Livden JK, Morken T, Mork NJ. Clobetasol propionate followed by calcipotriol is superior to calcipotriol alone in topical treatment of psoriasis. J Eur Acad Dermatol Venereol 1998; 11(1): 19-24.
116. Perez A, Chen TC, Turner A, Raab R, Bhawan J, Poche P, Holick MF. Efficacy and safety of topical calcitriol (1,25-dihydroxyvitamin d3) for the treatment of psoriasis. Br J Dermatol 1996; 134(2): 238-46.
117. Hölzle E, Hönigsmann H, Röcken M, Ghoreschi K, Lehmann P. Empfehlungen zur Phototherapie und Photochemotherapie. JDDG 2003; 1: 985-1000.
118. Ramsay CA, Schwartz BE, Lowson D, Papp K, Bolduc A, Gilbert M. Calcipotriol cream combined with twice weekly broad-band UVB phototherapy: a safe, effective and UVB-sparing antipsoriatric combination treatment. The Canadian Calcipotriol and UVB Study Group. Dermatology 2000; 200(1): 17-24.
119. Ring J, Kowalzick L, Christophers E, Schill WB, Schopf E, Stander M, Wolff HH, Altmeyer P. Calcitriol 3 microg g-1 ointment in combination with ultraviolet B phototherapy for the treatment of plaque psoriasis: results of a comparative study. Br J Dermatol 2001; 144(3): 495-9.
120. Petrozzi JW. Topical steroids and UV radiation in psoriasis. Arch Dermatol 1983; 119(3): 207-10.
121. Coven TR, Burack LH, Gilleaudeau R, Keogh M, Ozawa M, Krueger JG. Narrowband UV-B produces superior clinical and histopathological resolution of moderate-to-severe psoriasis in patients compared with broadband UVB. Arch Dermatol 1997; 133: 514-22.
122. Snellman E, Klimenko T, Rantanen T. Randomized Half-side Comparison of Narrowband UVB and Trimethylpsoralen Bath. Acta Derm Venereol 2004; 84(2): 132-137.
123. Gordon PM, Diffey BL, Matthews JNS, Farr PM. A randomised comparison of narrow-band TL-01 phototherapy and PUVA photochemotherapy for psoriasis. J Am Acad Dermatol 1999; 41: 728-32.
124. Leenutaphong V, Nimkulrat P, Sudtim S. Comparison of phototherapy two times and four times a week with low doses of narrow-band ultraviolet B in Asian patients with psoriasis. Photodermatol Photoimmunol Photomed 2000; 16(5): 202-6.
125. Grundmann-Kollmann M, Ludwig R, Zollner TM, Ochsendorf F, Thaci D, Boehncke WH, Krutmann J, Kaufmann R, Podda M. Narrowband UVB and cream psoralen-UVA combination therapy for plaque-type psoriasis. J Am Acad Dermatol 2004; 50(5): 734-9.
126. Katugampola GA, Rees AM, Lanigan SW. Laser treatment of psoriasis. Br J Dermatol 1995; 133(6): 909-13.
127. Housman TS, Pearce DJ, Feldman SR. A maintenance protocol for psoriasis plaques cleared by the 308 nm excimer laser. J Dermatolog Treat 2004; 15(2): 94-7.
128. Trehan M und Taylor CR. Medium-dose 308-nm excimer laser for the treatment of psoriasis. J Am Acad Dermatol 2002; 47(5): 701-8.
129. Feldman SR, Mellen BG, Housman TS, Fitzpatrick RE, Geronemus RG, Friedman PM, Vasily DB, Morison WL. Efficacy of the 308-nm excimer laser for treatment of psoriasis: results of a multicenter study. J Am Acad Dermatol 2002; 46(6): 900-6.
130. Parrish JA, Fitzpatrick TB, Tannenbaum L, Pathak MA. Photochemotherapy of psoriasis with oral methoxsalen and longwave ultraviolet light. N Engl J Med 1974; 291: 1207-11.
131. Kirby B, Buckley DA, Rogers S. Large increments in psoralen-ultraviolet A (PUVA) therapy are unsuitable for fair-skinned individuals with psoriasis. Br J Dermatol 1999; 140(4): 661-6.
132. Buckley DA, Healy E, Rogers S. A comparison of twice-weekly MPD-PUVA regimens for the treatment psoriasis. Br J Dermatol 1995; 133: 417-22.
133. Berg M und Ros AM. Treatment of psoriasis with psoralens and ultraviolet A. A double-blind comparison of 8-methoxypsoralen and 5-methoxypsoralen. Photodermatol Photoimmunol Photomed 1994; 10: 217-20.
134. Cooper EJ, Herd RM, Priestley GC, Hunter JA. A comparison of bathwater and oral delivery of 8-methoxypsoralen in PUVA therapy for plaque psoriasis. Clin Exp Dermatol 2000; 25(2): 111-4.
135. Collins P und Rogers S. Bath-water compared with oral delivery of 8-methoxypsoralen PUVA therapy for chronic plaque psoriasis. Br J Dermatol 1992; 127(4): 392-5.
136. Calzavara-Pinton PG, Ortel B, Honigsmann H, Zane C, De Panfilis G. Safety and effectiveness of an aggressive and individualized bath-PUVA regimen in the treatment of psoriasis. Dermatology 1994; 189(3): 256-9.
137. Barth J, Dietz O, Heilmann S, Kadner H, Kraensel H, Meffert H, Metz D, Pinzer B, Schiller F. Fotochemotherapie mit 8-Methoxypsoralen und UVA bei Psoriasis vulgaris. Dermatol Monatsschr 1978; 164(6): 401-7.
138. Khurshid K, Haroon TS, Hussain I, Pal SS, Jahangir M, Zaman T. Psoralen-ultraviolet A therapy vs. psoralen-ultraviolet B therapy in the treatment of plaque-type psoriasis: our experience with fitzpatrick skin type IV. Int J Dermatol 2000; 39(11): 865-7.
139. Arnold WP, van Andel P, de Hoop D, de Jong-Tieben L, Visser-van Andel M. A comparison of the effect of narrow-band ultraviolet B in the treatment of psoriasis after salt-water baths and after 8-methoxypsoralen baths. Br J Dermatol 2001; 145(2): 352-4.
140. Park YK, Kim HJ, Koh YJ. Combination of photochemotherapy (PUVA) and ultraviolet B (UVB) in the treatment of psoriasis vulgaris. J Dermatol 1988; 15(1): 68-71.
141. Kabat-Zinn J, Wheeler E, Light T, Skillings A, Scharf MJ, Cropley TG, Hosmer D, Bernhard JD. Influence of a mindfulness meditation-based stress reduction intervention on rates of skin clearing in patients with moderate to severe psoriasis undergoing phototherapy (UVB) and photochemotherapy (PUVA). Psychosomatic medicine 1998; 60(5): 625-632.
142. Robertson DB, McCarty JR, Jarratt M. Treatment of psoriasis with 8-methoxypsoralen and sunlight. South Med J 1978; 71(11): 1345-9.
143. Fleischer ABJ, Clark AR, Rapp SR, Reboussin DM, Feldman SR. Commercial tanning bed treatment is an effective psoriasis treatment: results from an uncontrolled clinical trial. J Invest Dermatol 1997; 109(2): 170-4.
144. Frappaz A und Thivolet J. Calcipotriol in combination with PUVA: a randomized double blind placebo study in severe psoriasis. Eur J Derm 1993; 3: 351-354.
145. Rogers S, Marks J, Shuster S, Briffa DV, Warin A, Greaves M. Comparison of photochemotherapy and dithranol in the treatment of chronic plaque psoriasis. Lancet 1979; 1(8114): 455-8.
146. Vella Briffa D, Rogers S, Greaves MW, Marks J, Shuster S, Warin AP. A randomized, controlled clinical trial comparing photochemotherapy with dithranol in the initial treatment of chronic plaque psoriasis. Clin Exp Dermatol 1978; 3(4): 339-47.
147. Parker S, Coburn P, Lawrence C, Marks J, Shuster S. A randomized double-blind comparison of PUVA-etretinate and PUVA-placebo in the treatment of chronic plaque psoriasis. Br J Dermatol 1984; 110(2): 215-20.
148. Dover JS, McEvoy MT, Rosen CF, Arndt KA, Stern RS. Are topical corticosteroids useful in phototherapy for psoriasis? J Am Acad Dermatol 1989; 20(5 Pt 1): 748-54.
149. Hanke CW, Steck WD, Roenigk HH, Jr. Combination therapy for psoriasis. Psoralens plus long-wave ultraviolet radiation with betamethasone valerate. Arch Dermatol 1979; 115(9): 1074-7.
150. Koo JY, Lowe NJ, Lew-Kaya DA, Vasilopoulos AI, Lue JC, Sefton J, Gibson JR. Tazarotene plus UVB phototherapy in the treatment of psoriasis. J Am Acad Dermatol 2000; 43(5 Pt 1): 821-8.
151. McBride SR, Walker P, Reynolds NJ. Optimizing the frequency of outpatient short-contact dithranol treatment used in combination with broadband ultraviolet B for psoriasis: a randomized, within-patient controlled trial. Br J Dermatol 2003; 149(6): 1259-65.
152. Gottlieb A, Krueger JG, Bright R, Ling M, Lebwohl M, Kang S, Feldman S, Spellman M, Wittkowski K, Ochs HD, Jardieu P, Bauer R, White M, Dedrick R, Garovoy M. Effects of administration of a single dose of a humanized monoclonal antibody to CD11a on the immunobiology and clinical activity of psoriasis. J Am Acad Dermatol 2000; 42(3): 428-35.
153. Gordon KB, Papp KA, Hamilton TK, Walicke PA, Dummer W, Li N, Bresnahan BW, Menter A. Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. JAMA 2003; 290(23): 3073-80.
154. Lebwohl M, Tyring SK, Hamilton TK, Toth D, Glazer S, Tawfik NH, Walicke P, Dummer W, Wang X, Garovoy MR, Pariser D. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med 2003; 349(21): 2004-13.
155. Leonardi CL, Papp KA, Gordon KB, Menter A, Feldman SR, Caro I, Walicke PA, Compton PG, Gottlieb AB. Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial. J Am Acad Dermatol 2005; 52(3 Pt 1): 425-33.
156. Menter A, Gordon K, Carey W, Hamilton T, Glazer S, Caro I, Li N, Gulliver W. Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis. Arch Dermatol 2005; 141(1): 31-8.
157. Papp K, Bissonnette R, Krüger JG, Carey W, Gratton D, Gulliver WP, Lui H. The Treatment of moderate to severe psoriasis with a new anti-CD11a monoclonal antibody. J Am Acad Dermatol 2001; 45(5): 665-674.
158. Gottlieb AB, Gordon KB, Lebwohl MG, Caro I, Walicke PA, Li N, Leonardi CL. Extended efalizumab therapy sustains efficacy without increasing toxicity in patients with moderate to severe chronic plaque psoriasis. J Drugs Dermatol 2004; 3(6): 614-24.
159. Menter A, Leonardi CL, Sterry W, Bos JD, Papp KA. Long-term management of plaque psoriasis with continuouse efalizumab therapy. J Am Acad Derm in press
160. Menter A, Kosinski M, Bresnahan BW, Papp KA, Ware JE, Jr. Impact of efalizumab on psoriasis-specific patient-reported outcomes. Results from three randomized, placebo-controlled clinical trials of moderate to severe plaque psoriasis. J Drugs Dermatol 2004; 3(1): 27-38.
161. Gordon KB, Koo JYM, Feldman SR, Menter A, Krueger G. Definitions of measures of effect duration for psoriasis treatments. Psoriasis Forum 2002; 8(3): 1-5.
162. Ettehadi P, Greaves MW, Wallach D, Aderka D, Camp RD. Elevated tumour necrosis factor-alpha (TNF-alpha) biological activity in psoriatic skin lesions. Clin Exp Immunol 1994; 96(1): 146-51.
163. Mussi A, Bonifati C, Carducci M, D'Agosto G, Pimpinelli F, D'Urso D, D'Auria L, Fazio M, Ameglio F. Serum TNF-alpha levels correlate with disease severity and are reduced by effective therapy in plaque-type psoriasis. J Biol Regul Homeost Agents 1997; 11(3): 115-8.
164. Moreland LW, Schiff MH, Baumgartner SW, Tindall EA, Fleischmann RM, Bulpitt KJ, Weaver AL, Keystone EC, Furst DE, Mease PJ, Ruderman EM, Horwitz DA, Arkfeld DG, Garrison L, Burge DJ, Blosch CM, Lange ML, McDonnell ND, Weinblatt ME. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 1999; 130(6): 478-86.
165. Mease PJ, Kivitz AJ, Burch FX, Siegel EL, Cohen SB, Ory P, Salonen D, Rubenstein J, Sharp JT, Tsuji W. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 2004; 50(7): 2264-72.
166. Gottlieb AB, Matheson RT, Lowe N, Krueger GG, Kang S, Goffe BS, Gaspari AA, Ling M, Weinstein GD, Nayak A, Gordon KB, Zitnik R. A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol 2003; 139(12): 1627-32; discussion 1632.
167. Leonardi CL, Powers JL, Matheson RT, Goffe BS, Zitnik R, Wang A, Gottlieb AB. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003; 349(21): 2014-22.
168. Costanzo A, Mazzotta A, Papoutsaki M, Nistico S, Chimenti S. Safety and efficacy study on etanercept in patients with plaque psoriasis. Br J Dermatol 2005; 152(1): 187-9.
169. Klareskog L, Moreland LM, Bohen SB. Global safety and efficacy of up to five years of etanercept (Enbrel) therapy. Arthritis Rheum 2001; 44(7 Suppl)
170. Moreland LW, Cohen SB, Baumgartner SW. Etanercept (Enbrel) monotherapy for more than 5 years in patients with DMARD-refrectory rheumatoid arthritis. Arthritis Rheum 2002; 46(Suppl): 533.
171. Holman J, Wallis WJ, Sabath DF. Tuberculosis reports with etanercept (Enbrel) therapy. Ann Dis Rheum 2002; 61(Suppl: Abstr. Nr. 0024)
172. Fachinformation, Wyeth; aktuelle Version.
173. Lebwohl M, Gottlieb A, Wallis W, al. e. Safety and efficacy of over 7 years of etanercept therapy in a global population of patients with rheumatoid arthritis. J Am Acad Dermatol 2005; 52(Suppl., P2792)
174. Antoni C, Krueger GG, de Vlam K, Birbara C, Beutler A, Guzzo C, Zhou B, Dooley LT, Kavanaugh A. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis 2005
175. Gottlieb AB, Evans R, Li S, Dooley LT, Guzzo CA, Baker D, Bala M, Marano CW, Menter A. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol 2004; 51(4): 534-42.
176. Chaudhari U, Romano P, Mulcahy LD, Dooley LT, Baker DG, Gottlieb AB. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 2001; 357(9271): 1842-7.
177. Schopf RE, Aust H, Knop J. Treatment of psoriasis with the chimeric monoclonal antibody against tumor necrosis factor alpha, infliximab. J Am Acad Dermatol 2002; 46(6): 886-91.
178. Gottlieb AB, Chaudhari U, Mulcahy LD, Li S, Dooley LT, Baker DG. Infliximab monotherapy provides rapid and sustained benefit for plaque-type psoriasis. J Am Acad Dermatol 2003; 48(6): 829-35.
179. Fachinformation, essex pharma; aktuelle Version.
180. Müller W und Hermann B. Beeinflussung der Psoriasis durch Cyclosporin A. Dtsch Med Wochenschr 1979; 104: 1047.
181. Koo J. A randomized, double-blind study comparing the efficacy, safety and optimal dose of two formulations of cyclosporin, Neoral and Sandimmun, in patients with severe psoriasis. OLP302 Study Group. Br J Dermatol 1998; 139(1): 88-95.
182. Sterry W, Barker J, Boehncke WH, Bos JD, Chimenti S, Christophers E, De La Brassinne M, Ferrandiz C, Griffiths C, Katsambas A, Kragballe K, Lynde C, Menter A, Ortonne JP, Papp K, Prinz J, Rzany B, Ronnevig J, Saurat JH, Stahle M, Stengel FM, Van De Kerkhof P, Voorhees J. Biological therapies in the systemic management of psoriasis: International Consensus Conference. Br J Dermatol 2004; 151(Suppl 69): 3-17.
183. Mrowietz U. Georg Thieme Verlag Stuttgart (2003), S. 107. New York. Ciclosporin in der Dermatologie.
184. Powles AV, Baker BS, McFadden JP, Rutman AJ, Griffiths CEM, Fry L. Intralesional injection of cyclosporin in psoriasis. Lancet 1988; 1: 537.
185. Powles AV, Baker BS, McFadden JP, Valdimarsson H, Fry L. Intralesional cyclosporin in psoriasis. Acta Derm Venereol Suppl (Stockh) 1989; 146: 148-9; discussion 149-50.
186. Wong RL, Winslow CM, Cooper KD. The mechanism of action of cyclosporin A in the treatment of psoriasis. Immunol today 1993; 14: 69-73.
187. Thaci D, Brautigam M, Kaufmann R, Weidinger G, Paul C, Christophers E. Body-weight-independent dosing of cyclosporine micro-emulsion and three times weekly maintenance regimen in severe psoriasis. A randomised study. Dermatology 2002; 205(4): 383-8.
188. Ho VC, Griffiths CE, Berth-Jones J, Papp KA, Vanaclocha F, Dauden E, Beard A, Puvanarajan L, Paul C. Intermittent short courses of cyclosporine microemulsion for the long-term management of psoriasis: a 2-year cohort study. J Am Acad Dermatol 2001; 44(4): 643-51.
189. Mahrle G, Schulze HG, Färber L, Weidinger G, Steigleder GK. Low-dose short-term cyclosporine versus etretinate in psoriasis: improvement of skin, nail and joint involvement. J Am Acad Dermatol 1995; 32(1): 78-88.
190. Nakayama J, Hori Y, Nakagawa H, Ishibashi Y, Horikoshi T, Ozawa A, Sugai J, Ohkido M. Comparison of two therapeutic regimens, continous monotherapy and intermittent therapy, for long-term maintenance of remission of psoriasis with cyclosporin A. Eur J Derm 1996; 6: 341-343.
191. Ellis CN, Fradin MS, Messana JM, Brown MD, Siegel MT, Howland Hartley A. Cyclosporine for plaque-type psoriasis. Results of a multidose, double-blind trial. N Engl J Med 1991; 324: 277-84.
192. Elder C, Moore M, Chang CT, Jin J, Charnick S, Nedelman J, Cohen A, Guzzo C, Lowe N, Simpson K. Efficacy and pharmacokinetics of two formulations of cyclosporine in patients with psoriasis. J Clin Pharmacol 1995; 35: 865-875.
193. Engst R und Huber J. Ergebnisse einer Cyclosporin-behandlung bei schwerer, chronischer Psoriasis vulgaris. Hautarzt 1989; 40: 186-9.
194. Laburte C, Grossman R, Abi-Rached J, Abeywickrama KM, Dubertret L. Efficacy and safety of oral cyclosporine A (CYA; Sandimmun) for longterm treatment of chronic severe plaque psoriasis. Br J Dermatol 1994; 130: 366-75.
195. Meffert H, Braeutigam M, Faerber L, Weidinger G. Low-dose (1,25 mg/kg) Cyclosporine A: Treatment of psoriasis and Investigation of the influence on lipid profile. Acta Derm Venereol 1997; Suppl 77: 137-41.
196. Finzi AF, Mozzanica N, Pigatto PD, Cattaneo A, Ippolito F. Cyclosporine versus etretinate: Italian multicentre comparative trial in severe psoriasis. Dermatology 1993; 187(Suppl. 1): 8-18.
197. Heydendael VM, Spuls PI, Opmeer BC, de Borgie CA, Reitsma JB, Goldschmidt WF, Bossuyt PM, Bos JD, de Rie MA. Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. N Engl J Med 2003; 349(7): 658-65.
198. Levell NJ, Shuster S, Munro CS, Friedmann PS. Remission of ordinary psoriasis following a short clearance course of cyclosporin. Acta Derm Venereol 1995; 75(1): 65-9.
199. Reitamo S, Spuls P, Sassolas B, Lahfa M, Claudy A, Griffiths CE. Efficacy of sirolimus (rapamycin) administered concomitantly with a subtherapeutic dose of cyclosporin in the treatment of severe psoriasis: a randomized controlled trial. Br J Dermatol 2001; 145(3): 438-45.
200. Grossman RM, Thivolet J, Claudy A, Souteyrand P, Guilhou JJ, Thomas P, Amblard P, Belaich S, de Belilovsky C, de la Brassinne M, et al. A novel therapeutic approach to psoriasis with combination calcipotriol ointment and very low-dose cyclosporine: results of a multicenter placebo-controlled study. J Am Acad Dermatol 1994; 31(1): 68-74.
201. Finzi AF, Mozzanica N, Cattaneo A, Chiappino G, Pigatto PD. Effectiveness of cyclosporine treatment in severe psoriasis: A clinical and immunologic study. J Am Acad Dermatol 1989; 21: 91-7.
202. Higgins E, Munro C, Marks J, Friedmann PS, Shuster S. Relapse rates in moderately severe chronic psoriasis treated with cyclosporine A. Br J Dermatol 1989; 121: 71-4.
203. Marcil I und Stern RS. Squamous-cell cancer of the skin in patients given PUVA and ciclosporin: nested cohort crossover study. Lancet 2001; 358(9287): 1042-5.
204. Paul CF, Ho VC, McGeown C, Christophers E, Schmidtmann B, Guillaume JC, Lamarque V, Dubertret L. Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 y cohort study. J Invest Dermatol 2003; 120(2): 211-6.
205. van de Kerkhof PC, Cambazard F, Hutchinson PE, Haneke E, Wong E, Souteyrand P, Damstra RJ, Combemale P, Neumann MH, Chalmers RJ, Olsen L, Revuz J. The effect of addition of calcipotriol ointment (50 micrograms/g) to acitretin therapy in psoriasis. Br J Dermatol 1998; 138(1): 84-9.
206. Agnew KL und Bunker CB. Multiple cutaneous squamous carcinoma in a psoriatic associated with ciclosporin, alcohol abuse and ultraviolet radiation exposure which were suppressed by acitretin. J Eur Acad Dermatol Venereol 2003; 17(1): 113-4.
207. Petzelbauer P, Honigsmann H, Langer K, Anegg B, Strohal R, Tanew A, Wolff K. Cyclosporin A in combination with photochemotherapy (PUVA) in the treatment of psoriasis. Br J Dermatol 1990; 123(5): 641-7.
208. Franchi C, Cainelli G, Frigerio E, Garutti C, Altomare GF. Association of cyclosporine and 311 nm UVB in the treatment of moderate to severe forms of psoriasis: a new strategic approach. Int J Immunopathol Pharmacol 2004; 17(3): 401-6.
209. Clark CM, Kirby B, Morris AD, Davison S, Zaki I, Emerson R, Saihan EM, Chalmers RJ, Barker JN, Allen BR, Griffiths CE. Combination treatment with methotrexate and cyclosporin for severe recalcitrant psoriasis. Br J Dermatol 1999; 141(2): 279-82.
210. Ameen M, Smith HR, Barker JN. Combined mycophenolate mofetil and cyclosporin therapy for severe recalcitrant psoriasis. Clin Exp Dermatol 2001; 26(6): 480-3.
211. Balasubramaniam P, Stevenson O, Berth-Jones J. Fumaric acid esters in severe psoriasis, including experience of use in combination with other systemic modalities. Br J Dermatol 2004; 150(4): 741-6.
212. Kokelj F, Torsello P, Plozzer C. Calcipotriol improves the efficacy of cyclosporine in the treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol 1998; 10(2): 143-6.
213. Mrowietz U und Asadullah K. Dimethylfumarate for psoriasis: more than a dietary curiosity. Trends Mol Med 2005; 11(1): 43-8.
214. Vandermeeren M, Janssens S, Borgers M, Geysen J. Dimethylfumarate is an inhibitor of cytokine-induced E-selectin, VCAM-1, and ICAM-1 expression in human endothelial cells. Biochem Biophys Res Commun 1997; 234(1): 19-23.
215. Litjens NH, Nibbering PH, Barrois AJ, Zomerdijk TP, Van Den Oudenrijn AC, Noz KC, Rademaker M, Van De Meide PH, Van Dissel JT, Thio B. Beneficial effects of fumarate therapy in psoriasis vulgaris patients coincide with downregulation of type 1 cytokines. Br J Dermatol 2003; 148(3): 444-51.
216. Zhu K und Mrowietz U. Inhibition of dendritic cell differentiation by fumaric acid esters. J Invest Dermatol 2001; 116(2): 203-8.
217. Asadullah K, Schmid H, Friedrich M, Randow F, Volk HD, Sterry W, Docke WD. Influence of monomethylfumarate on monocytic cytokine formation - explanation for adverse and therapeutic effects in psoriasis? Arch Dermatol Res 1997; 289(11): 623-30.
218. de Jong R, Bezemer AC, Zomerdijk TP, van de Pouw-Kraan T, Ottenhoff TH, Nibbering PH. Selective stimulation of T helper 2 cytokine responses by the anti-psoriasis agent monomethylfumarate. Eur J Immunol 1996; 26(9): 2067-74.
219. Ockenfels HM, Schultewolter T, Ockenfels G, Funk R, Goos M. The antipsoriatic agent dimethylfumarate immunomodulates T-cell cytokine secretion and inhibits cytokines of the psoriatic cytokine network. Br J Dermatol 1998; 139(3): 390-5.
220. Treumer F, Zhu K, Glaser R, Mrowietz U. Dimethylfumarate is a potent inducer of apoptosis in human T cells. J Invest Dermatol 2003; 121(6): 1383-8.
221. Altmeyer PJ, Matthes U, Pawlak F, Hoffmann K, Frosch PJ, Ruppert P, Wassilew SW, Horn T, Kreysel HW, Lutz G, Barth J, Rietzschel I, Joshi R. Antipsoriatic effect of fumaric acid derivatives. Results of a multicentre double-blind study in 100 patients. J Am Acad Dermatol 1994; 30(6): 977-81.
222. Gollnick H, Altmeyer P, Kaufmann R, Ring J, Christophers E, Pavel S, Ziegler J. Topical calcipotriol plus oral fumaric acid is more effective and faster acting than oral fumaric acid monotherapy in the treatment of severe chronic plaque psoriasis vulgaris. Dermatology 2002; 205(1): 46-53.
223. Kolbach DN und Nieboer C. Fumaric acid therapy in psoriasis: results and side effects of 2 years of treatment. J Am Acad Dermatol 1992; 27(5 Pt 1): 769-71.
224. Nugteren-Huying WM, van der Schroeff JG, Hermans J, Suurmond D. [Fumaric acid therapy in psoriasis; a double-blind, placebo-controlled study]. Ned Tijdschr Geneeskd 1990; 134(49): 2387-91.
225. Altmeyer P, Hartwig R, Matthes U. Das Wirkungs- und Sicherheitsprofil von Fumarsäureestern in der oralen Langzeittherapie bei schwerer therapieresistenter Psoriasis vulgaris. Eine Untersuchung an 83 Patienten. Hautarzt 1996; 47(3): 190-6.
226. Bayard W, Hunziker T, Krebs A, Speiser P, Joshi R. Perorale Langzeitbehandlung der Psoriasis mit Fumarsäurederivaten. Hautarzt 1987; 38(5): 279-85.
227. Carboni I, De Felice C, De Simoni I, Soda R, Chimenti S. Fumaric acid esters in the treatment of psoriasis: an Italian experience. J Dermatolog Treat 2004; 15(1): 23-6.
228. Mrowietz U, Christophers E, Altmeyer P. Treatment of psoriasis with fumaric acid esters: results of a prospective multicentre study. German Multicentre Study. Br J Dermatol 1998; 138(3): 456-60.
229. Nieboer C, de Hoop D, van Loenen AC, Langendijk PN, van Dijk E. Systemic therapy with fumaric acid derivates: new possibilities in the treatment of psoriasis. J Am Acad Dermatol 1989; 20(4): 601-8.
230. Hoefnagel JJ, Thio HB, Willemze R, Bouwes Bavinck JN. Long-term safety aspects of systemic therapy with fumaric acid esters in severe psoriasis. Br J Dermatol 2003; 149(2): 363-9.
231. Gubner R, August S, Ginsberg V. Therapeutic suppression of tissue reactivity: effect of Aminopterin in Rheumatoid Arthritis and Psoriasis. Am J M Sc 1951; 221: 176-82.
232. Smith KC. Systemic therapy of psoriasis using methotrexate. Skin Therapy Lett. 2000; 6(3): 1-2; 5.
233. Weinstein GD und Frost P. Methotrexate for psoriasis. A new therapeutic schedule. Arch Dermatol 1971; 103: 33-8.
234. Roenigk HH, Jr., Auerbach R, Maibach H, Weinstein G, Lebwohl M. Methotrexate in psoriasis: Consensus Conference. J Am Acad Dermatol 1998; 38(3): 478-85.
235. Collins P und Rogers S. The efficacy of methotrexate in psoriasis - a review of 40 cases. Clin Exp Dermatol 1992; 17: 257-60.
236. van Dooren-Greebe RJ. Interruption of long-term methotrexate treatment in psoriasis. Acta Derm Venereol 1995; 75: 393-6.
237. van Ede AE, Laan RF, Rood MJ, Huizinga TW, van de Laar MA, van Denderen CJ, Westgeest TA, Romme TC, de Rooij DJ, Jacobs MJ, de Boo TM, van der Wilt GJ, Severens JL, Hartman M, Krabbe PF, Dijkmans BA, Breedveld FC, van de Putte LB. Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight week, multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum 2001; 44(7): 1515-24.
238. Ortiz Z, Shea B, Suarez Almazor M, Moher D, Wells G, Tugwell P. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. Cochrane Database Syst Rev 2000(2): CD000951.
239. Duhra P. Treatment of gastrointestinal symptoms associated with methotrexate therapy for psoriasis. J Am Acad Dermatol 1993; 28(3): 466-9.
240. Nyfors A und Brodthagen H. Methotrexate for psoriasis in weekly oral doses without any adjunctive therapy. Dermatologica 1970; 140: 345-55.
241. Paul BS, Momtaz K, Stern RS, Arndt KA, Parrish JA. Combined methotrexate - ultraviolet B therapy in the treatment of psoriasis. J Am Acad Dermatol 1982; 7(6): 758-62.
242. Morison WL, Momtaz K, Parrish JA, Fitzpatrick TB. Combined methotrexate-PUVA therapy in the treatment of psoriasis. J Am Acad Dermatol 1982; 6(1): 46-51.
243. Nyfors A. Benefits and adverse drug experiences during long-term methotrexate treatment of 248 psoriatics. Dan Med Bull 1978; 25(5): 208-11.
244. van Dooren-Greebe RJ, Kuijpers ALA, Mulder J, Boo Td, Kerkhof PCM. Methotrexate revisited: effects of long term treatment in psoriasis. Br J Dermatol 1994; 130: 204-10.
245. Newman M, Auerbach R, Feiner H, Holzman RS, Shupack J, Migdal P. The role of liver biopsies in psoriatic patients receiving long-term methotrexate treatment. Arch Dermatol 1989; 125: 1218-24.
246. Whiting-O'Keefe QE, Fye KH, Sack KD. Methotrexate and histologic hepatic abnormalities: a meta-analysis. Am J Med 1991; 90: 711-6.
247. Said S, Jeffes EW, Weinstein GD. Methotrexate. Clin Dermatol 1997; 15(5): 781-97.
248. Menter MA, See JA, Amend WJ, Ellis CN, Krueger GG, Lebwohl M, Morison WL, Prystowsky JH, Roenigk HH, Jr., Shupack JL, Silverman AK, Weinstein GD, Yocum DE, Zanolli MD. Proceedings of the Psoriasis Combination and rotation therapy conference. J Am Acad Dermatol 1996; 34(2 Pt 1): 315-21.
249. Zachariae H, Grunnet E, Sogaard H. Liver biopsy in methotrexate-treated psoriatics-a re-evalution. Acta Derm Venereol 1975; 55(4): 291-6.
250. Zachariae H, Kragballe K, Sogaard H. Methotrexate induced liver cirrhosis. Studies including serial liver biopsies during continued treatment. Br J Dermatol 1980; 102(4): 407-12.
251. Nyfors A. Liver biopsies from psoriatics related to methotrexate therapy. 3. Findings in post-methotrexate liver biopsies from 160 psoriatics. Acta Pathol Microbiol Scand [A] 1977; 85(4): 511-8.
252. Robinson JK, Baughman RD, Auerbach R, Cimis RJ. Methotrexate hepatotoxicity in psoriasis. Consideration of liver biopsies at regular intervals. Arch Dermatol 1980; 116(4): 413-5.
253. Malatjalian DA, Ross JB, Williams CN, Colwell SJ, Eastwood BJ. Methotrexate hepatotoxicity in psoriatics: report of 104 patients from Nova Scotia, with analysis of risks from obesity, diabetes and alcohol consumption during long term follow-up. Can J Gastroenterol 1996; 10(6): 369-75.
254. Boffa MJ, Chalmers RJ, Haboubi NY, Shomaf M, Mitchell DM. Sequential liver biopsies during longterm methotrexate treatment for psoriasis: a reappraisal. Br J Dermatol 1995; 133(5): 774-8.
255. Warin AP, Landells JW, Levene GM, Baker H. A prospective study of the effects of weekly oral methotrexate on liver biopsy. Br J Dermatol 1975; 93(3): 321-7.
256. Kuijpers ALA. Severe forms of psoriasis. Clinical and experimental studies. Proefschrift 1998
257. van Dooren-Greebe RJ, Kuijpers AL, Buijs WC, Kniest PH, Corstens FH, Nagengast FM, de Boo T, Willems JL, Duller P, van de Kerkhof PC. The value of dynamic hepatic scintigraphy and serum aminoterminal propeptide of type III procollagen for early detection of methotrexate-induced hepatic damage in psoriasis patients. Br J Dermatol 1996; 134(3): 481-7.
258. Zachariae H, Sogaard H, Heickendorff L. Serum aminoterminal propeptide of type III procollagen. A non-invasive test for liver fibrogenesis in methotrexate-treated psoriatics. Acta Derm Venereol 1989; 69(3): 241-4.
259. Risteli J, Sogaard H, Oikarinen A, Risteli L, Karvonen J, Zachariae H. Aminoterminal propeptide of type III procollagen in methotrexate-induced liver fibrosis and cirrhosis. Br J Dermatol 1988; 119(3): 321-5.
260. Chalmers RJ, Kirby B, Smith A, Burrows P, Little R, Horan M, Hextall JM, Smith CH, Klaber M, Rogers S. Replacement of routine liver biopsy by procollagen III aminopeptide for monitoring patients with psoriasis receiving long-term methotrexate: a multicentre audit and health economic analysis. Br J Dermatol 2005; 152(3): 444-50.
261. Nyfors A und Jensen H. Frequency of malignant neoplasms in 248 long-term methotrexate-treated psoriatics. A preliminary study. Dermatologica 1983; 167(5): 260-1.
262. Rustin GJ, Newlands ES, Lutz JM, Holden L, Bagshawe KD, Hiscox JG, Foskett M, Fuller S, Short D. Combination but not single-agent methotrexate chemotherapy for gestational trophoblastic tumors increases the incidence of second tumors. J Clin Oncol 1996; 14(10): 2769-73.
263. Zachariae H. Liver biopsies and methotrexate: a time for reconsideration? J Am Acad Dermatol 2000; 42(3): 531-4.
264. Verschuur AC, Everdingen JJEv, Cohen EB, Chamuleau RAFM. Liver biopsy versus ultrasound in methotrexate-treated psoriasis: a decision analysis. Int J Dermatol 1992; 31(6): 404-9.
265. Sulganick J, Tan MH, Lenwohl M. Psoriasis. Forum 1997; 3: 5.
266. Moy RL, Kingston TP, Lowe NJ. Isotretinoin vs Etretinate therapy in generalized pustular and chronic psoriasis. Arch Dermatol 1985; 121: 1297-301.
267. Meffert H und Sönnichsen N. Acitretin in the treatment of severe psoriasis: a randomized double-blind study comparing Acitretin and Etretinate. Acta Derm Venereol 1989; 146: 176-7.
268. Ledo A, Martín M, Geiger JM, Marrón JM. Acitretin (RO 10-1670) in the treatment of severe psoriasis. A randomized double-blind parallel study comparing Acitretin and Etretinate. Int J Dermatol 1988; 27: 656-60.
269. Kragballe K, Jansen CT, Geiger JM, Bjerke JR, Falk ES, Gip L, Hjorth N, Lauharanta J, Mork NJ, Reunala T, et al. A double-blind comparison of acitretin and etretinate in the treatment of severe psoriasis. Results of a Nordic multicentre study. Acta Derm Venereol 1989; 69(1): 35-40.
270. Gollnick H, Bauer R, Brindley C, Orfanos CE, Plewig G, Wokalek H, Hoting E. Acitretin versus etretinate in psoriasis. Clinical and pharmacokinetic results of a German multicenter study. J Am Acad Dermatol 1988; 19(3): 458-68.
271. Goldfarb MT, Ellis CN, Gupta AK, Tincoff T, Hamilton TA, Voorhees JJ. Acitretin inproves psoriasis is a dose dependent fashion. J Am Acad Dermatol 1988; 18: 655-62.
272. Gollnick HP und Dümmler U. Retinoids. Clin Dermatol 1997; 15(5): 799-810.
273. Gupta AK, Goldfarb MT, Ellis CN, Voorhees JJ. Side-effect profile of acitretin therapy in psoriasis. J Am Acad Dermatol 1989; 20(6): 1088-93.
274. Caca-Biljanovska NG und V'Lckova-Laskoska MT. Management of guttate and generalized psoriasis vulgaris: prospective randomized study. Croat Med J 2002; 43(6): 707-12.
275. Lowe NJ, Prystowsky JH, Bourget T, Edelstein J, Nychay S, Armstrong R. Acitretin plus UVB therapy for psoriasis. Comparisons with placebo plus UVB and acitretin alone. J Am Acad Dermatol 1991; 24(4): 591-4.
276. Lebwohl M. Acitretin in combination with UVB or PUVA. J Am Acad Dermatol 1999; 41(3 Pt 2): S22-4.
277. Berbis P, Geiger JM, Vaisse C, Rognin C, Privat Y. Benefit of progressively increasing doses during the initial treatment with acitretin in psoriasis. Dermatologica 1989; 178(2): 88-92.
278. Gronhoj Larsen F, Steinkjer B, Jakobsen P, Hjorter A, Brockhoff PB, Nielsen-Kudsk F. Acitretin is converted to etretinate only during concomitant alcohol intake. Br J Dermatol 2000; 143(6): 1164-9.
279. Murray HE, Anhalt AW, Lessard R, Schacter RK, Ross JB, Stewart WD, Geiger JM. A 12-month treatment of severe psoriasis with acitretin: results of a Canadian open multicenter study. J Am Acad Dermatol 1991; 24(4): 598-602.
280. Saurat JH, Geiger JM, Amblard P, Beau J-C, Boulanger A, Claudy A, al. e. Randomized double-blind multicenter study comparing acitretin-PUVA and placebo-PUVA in the treatment of severe psoriasis. Dermatoligica 1988; 177: 218-24.
281. Lauharanta J und Geiger JM. A double-blind comparison of acitretin and etretinate in combination with bath PUVA in the treatment of extensive psoriasis. Br J Dermatol 1989; 121(1): 107-12.
282. Carlin CS, Callis KP, Krueger GG. Efficacy of acitretin and commercial tanning bed therapy for psoriasis. Arch Dermatol 2003; 139(4): 436-42.
283. Matz H, Orion E, Wolf R. Balneotherapy in dermatology. Dermatol Ther 2003; 16(2): 132-40.
284. Halevy S, Giryes H, Friger M, Sukenik H. Dead sea bath salt for the treatment of psoriasis vulgaris: A double- blind controlled study. Journal of the European Academy of Dermatology and Venereology 1997; 9(3): 237-242.
285. Kushelevsky AP, Harari M, Hristakieva E, Shani J. Climatotherapy of psoriasis and hypertension in elderly patients at the Dead-Sea. Pharmacol Res 1996; 34(1-2): 87-91.
286. Schmid-Ott G. Depth psychology-founded psychotherapy of psoriatic patients. Treatment of a patient with chronic recidivating psoriasis vulgaris. Dermatol Psychosom 2000; 1: 112-6.
287. Gupta MA, Gupta AK, Kirkby S, Schork NJ, Gorr SK, Ellis CN, Voorhees JJ. A psychocutaneous profile of psoriasis patients who are stress reactors. A study of 127 patients. Gen Hosp Psychiatry 1989; 11(3): 166-73.
288. Augustin M, Amon U, Bullinger M, Gieler U. Empfehlungen zur Erfassung von Lebensqualität in der Dermatologie. Dermatol Psychosom 2000; 1: 76-82.
289. De Korte J, Mombers FM, Sprangers MA, Bos JD. The suitability of quality-of-life questionnaires for psoriasis research: a systematic literature review. Arch Dermatol 2002; 138(9): 1221-7; discussion 1227.
290. Finlay AY, Khan GK, Luscombe DK, Salek MS. Validation of Sickness Impact Profile and Psoriasis Disability Index in Psoriasis. Br J Dermatol 1990; 123(6): 751-6.
291. Schmid-Ott G, Keins P, Fartasch M, Ring J, Lob-Corzilius T, von Rüden U, Wolf P. Atopic eczema prevention program in childhood and adolescene - a model project of the German Government. Dermatol Psychosom 2000; 1: 179-82.
292. Schmid-Ott G, Jaeger B, Adamek C, Koch H, Lamprecht F, Kapp A, Werfel T. Levels of circulating CD8+ T lymphocytes, natural killer cells, and eosinophils increase upon acute psychosocial stress in patients with atopic dermatitis. J Allergy Clin Immunol 2001; 107(1): 171-7.
293. Fortune DG, Richards HL, Kirby B, Bowcock S, Main CJ, Griffiths CE. A cognitive-behavioural symptom management programme as an adjunct in psoriasis therapy. Br J Dermatol 2002; 146(3): 458-65.
294. Tausk F und Whitmore SE. A pilot study of hypnosis in the treatment of patients with psoriasis. Psychother Psychosom 1999; 68(4): 221-5.
295. Zigmond AS und Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983; 67(6): 361-70.
296. Orfanos CE, Steigleder GK, Pullmann H, Bloch PH. Oral retinoid and UVB radiation: a new, alternative treatment for psoriasis on an out-patient basis. Acta Derm Venereol 1979; 59(3): 241-4.
297. Calzavara-Pinton P. Narrow band UVB (311 nm) phototherapy and PUVA photochemotherapy: a combination. J Am Acad Dermatol 1998; 38(5 Pt 1): 687-90.
298. Markham T, Rogers S, Collins P. Narrowband UV-B (TL-01) phototherapy vs oral 8-methoxypsoralen psoralen-UV-A for the treatment of chronic plaque psoriasis. Arch Dermatol 2003; 139(3): 325-8.
299. Calzavara-Pinton P, Ortel B, Carlino A, Honigsmann H, De Panfilis G. A reappraisal of the use of 5-methoxypsoralen in the therapy of psoriasis. Exp Dermatol 1992; 1(1): 46-51.
300. Henseler T, Wolff K, Hönigsmann H, Christophers E. Oral 8-methoxypsoralen photochemotherapy of psoriasis. The European PUVA Study: a cooperative study among 18 European centres. Lancet 1981; 11: 853-7.
301. Torras H, Aliaga A, Lopez-Estebaranz JL, Hernandez I, Gardeazabal J, Quintanilla E, Mascaro JM. A combination therapy of calcipotriol cream and PUVA reduces the UVA dose and improves the response of psoriasis vulgaris. J Dermatol Treat 2004; 15(2): 98-103.
302. Hacker SM und Rasmussen JE. The effect of flash lamp-pulsed dye laser on psoriasis. Arch Dermatol 1992; 128(6): 853-5.